|
ADVM | Adverum Biotechnologies, Inc. |
|
|
ADVM | Adverum Biotechnologies, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.32 |
| Leverage | 38.51% |
| Market Cap | $ 450.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -93.7m |
| Margin | -1062.83% |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California.